TDI 3.0 implementation. TDI Prevalence. Linda Montanari, Bruno Guarita

Size: px

Start display at page:

Download "TDI 3.0 implementation. TDI Prevalence. Linda Montanari, Bruno Guarita"

Lorraine Welch
5 years ago
Views:

1 TDI 3.0 implementation TDI Prevalence Linda Montanari, Bruno Guarita Lisbon, September 2015 Workshop 3.0 The role and value of data from drug treatment services (TDI working group)

2 TDI implementation

3 Main outcomes from survey TD started with drug phenomenon and creation of drug services Efforts in implementation/ progress on available information Improvement of coverage Efforts to increase harmonisation with EU standards Recent developments: Diversification of treatment New drug problems Online data collection Prevalence Legal substances and other addictions 3

4 Impact on drug policy: different levels of data utilization Information on trends and clients needs (e.g. FIN, IT) Input to national strategies and programmes (e.g. SK; SI) Develop specific projects, especially prevention projects (e.g. GE) Influence the allocation of financial resources (e.g. UK) 4

5 Data provided according to TDI ver countries provided data based on TDI countries use same case definition as TDI 3.0 New variables: N. of countries Lag to treatment 26 Living with children 23 HIV test 17 Needles sharing 17 OST 16 Polydrug use problem 16 Age at first OST 15 Age at first injection 15 HCV test 15 5

6 DRID and TDI Countries reporting in TDI and DRID (treatment centres) on HIV and HCV testing data (in RED: common countries) 6

7 Draft results from KI assessment 100% 90% 80% 70% 60% 50% % HIGH 30% 20% 10% 0% MEDIUM LOW 7

8 Medium term perspectives (from survey and this year s experience) Improve coverage Improve data collection on new variables More attention to data quality Explore further analysis within TDI and with other indicators Linkage with other registries and data consistency check (esp. DRID/TDI) Continue good collaboration EMCDDA/TDI experts EMCDDA to inform national governments about use of TDI data TDI Prevalence implementation 8

9 TDI Prevalence

10 Aim of the project 1. Estimate the total number of people in contact with treatment services 2. Improving the picture of the population with drug problems, even when they are considered as stabilised in treatment 3. Have information on treatment capacity and activity, which can be complemented by other tools and indicators 4. Identify a basic profile of the population in treatment, including those in long term treatment 10

11 A long process First idea for a project on TDI prevalence Discussion at the RTX NFPs 2006 Working group meeting 1 st Pilot data collection 2007 Feasibility assessment 2 nd Pilot data collection rd Pilot data collection RTX meeting 2013 Guidelines for data collection TDI and RTX meetings Final guidelines 2015 Template for data collection Final template st routine data collection nd routine data collection 11

12 Number of clients by group Data 2007 in 13 countries (N ) 2% % 2% 13% % % 13% 70% Never previously treated Previously treated In continuous treatment Opioids Cocaine Stmulants other than cocaine Cannabis Other drugs Source: 2008 and 2006 Pilot data collection in 13 countries Latvia was not included because it only has total number of clients 12

13 Guidelines 8 Mandatory items Treatment centre type, Year of starting treatment, Treatment status, Sex, Age, Primary Drug, Duration in treatment, Opioid Substitution Treatment (16 Voluntary items: same as TDI) Periodic data collection: every three year (2016, 2019, 2022, etc.) First year of data reporting to EMCDDA:

14 Template for TDI prevalence: FONTE Questions: Column Raw Only on continuous treatments Numbers Client s status New, Previously, Continuous Coverage By treatment centre As in TDI Type of treatment By sex As in TDI Primary drug By age As in TDI Primary drug By duration in treatment Specific Primary drug By OST Specific 14

15 Challenges for the future

16 Long term Alcohol??? Substance to be included in future European treatment demand monitoring system? (17 out of 23 countries include already alcohol) Individual records reported at EU level??? (implications at national level, from survey in out of 23 countries collect case level data at national level) Need for further harmonisation. item interpretation (e.g. primary drug, etc.)/training/ Other challenges????... 16

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information